Kec (092220) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
15 Jul, 2026Executive summary
Specializes in non-memory power semiconductors, with a global presence and strong export focus, especially to China, Japan, and the US.
Operates 12 overseas subsidiaries and sales networks, with two main consolidated subsidiaries in Thailand and China.
Recent acquisition of remaining shares in KEC Thailand Co., Ltd., raising ownership to 100% for business efficiency.
Financial highlights
Consolidated H1 2024 revenue: ₩128.6 billion, down from ₩206.9 billion in H1 2023.
Operating loss of ₩1.18 billion, a significant improvement from a ₩33.0 billion loss in H1 2023.
Net profit attributable to owners: ₩157 million, compared to a net loss of ₩36.1 billion in H1 2023.
Cash and cash equivalents at period end: ₩14.3 billion.
Total assets: ₩447.4 billion; total equity: ₩348.4 billion.
Outlook and guidance
Industry expects global semiconductor market to grow 13.1% in 2024, with SSTR segment rebounding by 10.3%.
Focus on expanding automotive semiconductor business and maintaining R&D investment for product innovation.
Latest events from Kec
- Revenue fell and losses narrowed in H1 2026, with strategic restructuring actions taken.092220
Q2 2026 - Revenue up 17.5% but net loss persists; global expansion and R&D investments ongoing.092220
Q4 2024 - Q1 2025 revenue reached KRW 63.6B with a net loss of KRW 2.28B amid ongoing R&D and global focus.092220
Q1 2025 - Net loss widened to KRW 26.6 billion on 5.6% lower sales, with ongoing investments in production capacity.092220
Q4 2025 - Revenue fell and losses narrowed, with full Thai subsidiary ownership and strong global focus.092220
Q3 2024 - H1 2025 revenue declined and losses persisted, but operational efficiency improved.092220
Q2 2025 - Q1 2026 saw a net loss, negative cash flow, and a reverse stock split to stabilize shares.092220
Q1 2026 - 2025 YTD sales fell to KRW 175.9B with a net loss of KRW 13.4B; major capital and R&D investments ongoing.092220
Q3 2025